Supplemental Online Content

Rao S, Lee GM, Razzaghi H, et al. Clinical features and burden of postacute sequelae of SARS-CoV-2 infection in children and adolescents. *JAMA Pediatr*. Published online August 15, 2022. doi:10.1001/jamapediatrics.2022.2800

eTable. Code Sets for Systemic and Syndromic Features of PASC and Medication Therapeutic Classes Associated With PASC

eFigure 1. Medication Therapeutic Classes Associated With PASC

eFigure 2. Kaplan-Meier Plot for Risk of Any Syndromic Feature of PASC

eFigure 3. Kaplan-Meier Plot for Risk of Any Systemic Feature of PASC

eFigure 4. Kaplan-Meier Plot for Risk of Any Medication Feature of PASC

eFigure 5. Kaplan-Meier Plot for Risk of Any Syndromic, Systemic, or Medication Feature of PASC

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Code Sets for Systemic and Syndromic Features of PASC and Medication Therapeutic Classes Associated With PASC

	Syndromic (symptoms, signs, non-specific laboratory abnormalities)	Systemic (diagnosed health conditions)	Medication Therapeutic Classes
Clinically predicted and empirically supported (i.e., lower limit of the 95% CI for the outcome was greater than 1)	Other changes in smell/taste Loss of smell Hair loss Chest pain Abnormal liver enzymes Generalized pain Anxiety symptoms Skin rashes Fever/chills Cardiorespiratory signs/symptoms Fatigue/malaise Diarrhea Allergies Skin signs/symptoms Nausea and vomiting General signs and symptoms Genitourinary signs and symptoms Genitourinary signs and symptoms	 COVID-19 Multisystem inflammatory syndrome PASC Acute respiratory distress syndrome Myocarditis Myositis Mental health treatment Fluid/electrolyte disturbance Disorders of teeth/gingiva Other/ill-defined heart diseasex Acute kidney injury Thrombophlebitis and thromboembolism Pneumonia Bronchiolitis Tonsilitis Other/specified inflammatory condition of skin Obesity Communication/motor disorders Respiratory failure Gastroenteritis 	 Antiarrhythmics, Class I and III Antiemetics/antinauseants Antiinflammatory and antirheumatic agents in combination Cough and cold preparations Systemic corticosteroids Corticosteroids with antiseptics Decongestants Direct acting antivirals Hypnotics/sedatives Opioids Parasympathomimetics Propulsives Cough suppressants and expectorants, combinations Nasal decongestants for systemic use
Clinically predicted but not empirically supported	 Abdominal pain Abdominal signs and symptoms Anger and aggression Anorexia Anxiety disorder Arthralgia Attention symptoms Balance problems 	 Academic developmental disorder Addison disease Alopecia areata Antiphospholipid syndrome Aplastic anemia Appendicitis Arrhythmias Arthritis Asthma Attention deficit hyperactivity disorder 	 ACE Inhibitors, plain Adrenergics, inhalants Antidepressants Antiepileptics Antihistamines for systemic use Antiinflammatory agents Antimigraine preparations Antithrombotic agents Beta blocking agents Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)

- Bruising and bleeding disorders
- Chilblain
- Cognitive impairment
- Cognitive signs and symptoms
- Coma
- Constipation
- Cough
- Delirium
- Depressive symptoms
- Diseases of the vocal cords and larynx
- Dizziness and syncope
- Dysphagia
- Emotional and behavioral signs and symptoms
- Genitourinary signs and symptoms
- Headache
- Loss of taste
- Myalgia
- Nasal congestion
- Neuraliga and neuritis
- Ocular pain
- Otalgia
- Pruritis
- Psychological symptoms, other
- Sleep-wake disorders
- Speech signs and symptoms
- Stress
- Visual disturbances
- Weight loss

- Autism spectrum disorder
- Autoimmune thyroiditis
- Avoidant and restrictive food intake
- Bipolar disorder
- Bronchitis
- Cardiomyopathy
- Catatonia
- Celiac disease
- Chronic kidney disease
- Chronic obstructive pulmonary disease and bronchiectasis
- Conduct disorder
- Dermatitis herpetiformis
- Developmental delay
- Diabetes mellitus
- Diabetes mellitus, type
 1
- Diabetes mellitus, type2
- Dysautonomia
- Encopresis
- Feeding and eating disorders
- Heart disease, other
- Hypertension
- Hypothyroidism
- Idiopathic thrombocytopenic purpura
- Inflammatory polyneuropathy
- Intellectual disability
- Kawasaki disease
- Major depression
- Minor depression
- Neonatal digestive and feeding disorders
- Oppositional defiant disorder
- Pericarditis
- Psoriasis
- Psychotic disorder
- Pulmonary fibrosis
- Rhabdomyolysis
- Schizoaffective disorder
- Schizophrenia
- Scleroderma

- Immunoglobulins
- Immunosuppressants
- Other drugs for obstructive airway diseases, inhalants
- Expectorants, excl. combinations with cough suppressants
- Other mineral supplements

Empirically	Superficial injury:	 Seizures and epilepsy Sexual dysfunction Sjogren syndrome Systemic lupus and other connective tissue disorders Takotsubo cardiomyopathy Temporal arteritis Thyroiditis Tic disorder Vitiligo 	Ultrasound contrast media
supported but not clinically predicted or evaluated as clinically plausible	Superficial injury; contusion	 Breast cancer Neurogenic/neuropathic arthropathy Personal/family history of disease Septicemia Mental health treatment Adverse effects of drugs and medicaments Newborn status Disorders of teeth and gingiva Influenza Other and ill-defined heart disease Complication of device, implant, or graft Contact dermatitis Intestinal infection Parasitic disease Other injuries Bacterial infections Diseases of white blood cells Tonsillitis Coagulation and hemorrhagic disorders Intestinal obstruction and ileus Postprocedural or postoperative complications Other specified encounters and counseling Hypotension 	 Ultrasound contrast media Allergens Irrigating solutions Anesthetics, local Ectoparasiticides, incl. scabicides Anesthetics, general Antiinflammatory/antirheumatic agents in combination Antispasmodics in combination with analgesics Corticosteroids, combinations with antibiotics Antiinfectives and antiseptics, excl. combinations with corticosteroids Bacterial vaccines Vitamin k and other hemostatics Other antibacterials Antiinflammatory agents and antiinfectives in combination Throat preparations Bacterial and viral vaccines, combined Corticosteroids, other combinations Anti-acne preparations for topical use Antifibrinolytics Other otologicals Antibiotics for topical use Ascorbic acid (vitamin C), incl. combinations Blood and related products Medicated dressings Local anesthetics


		 Other specified inflammatory condition of skin Viral infection Obesity Pleurisy, pleural effusion and pulmonary collapse Other specified status Complication of other surgical or medical care injury Other specified upper respiratory infections Inflammatory conditions of male genital organs Urinary tract infections Other specified and unspecified skin disorders Skin and subcutaneous tissue infections Administrative encounter Nervous system pain and pain syndromes Otitis media 	 All other therapeutic products Vitamin B12 and folic acid Viral vaccines Antispasmodics in combination with psycholeptics Muscle relaxants, peripherally acting agents Antifungals for topical use Antiseptics and disinfectants Other ophthalmologicals Corticosteroids and antiinfectives in combination Drugs for functional gastrointestinal disorders I.V. solution additives Other beta-lactam antibacterials Beta-lactam antibacterials, penicillins
Clinically predicted but outcome found to be of greater risk in test negative cohort (upper limit of 95% CI for outcome was less than 1)	 Balance problems Stress Cough Chilblain Abdominal pain 	 Feeding and eating disorders Seizures and epilepsy Major depression Minor depression Celiac disease Dysautonomia Autism spectrum disorder Intellectual disability 	 ACE inhibitors, plain Antidepressants Antiepileptics Antithrombotic agents Beta blocking agents Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Immunosuppressants

^a Codesets were developed from ICD codes, the full list of the code assignments to clusters is publicly available at https://github.com/PEDSnet/PASC.


eFigure 1. Medication Therapeutic Classes Associated With PASC

	aHR, 95% CI		
Cough and cold preparations	1.52 (1.18,1.96)		
Nasal decongestants for systemic use	1.46 (1.19,1.79)		
Corticosteroids with antiseptics	1.40 (1.13,1.74)		_
Opioids	1.38 (1.30,1.47)		
Decongestants	1.29 (1.21,1.37)		
Parasympathomimetics	1.28 (1.11,1.48)		
Hypnotics/sedatives	1.28 (1.21,1.35)		
Antiinflammatories	1.27 (1.22,1.32)		
Antiemetics	1.26 (1.21,1.32)		
Propulsives	1.25 (1.03,1.51)		
Direct acting antivirals	1.23 (1.02,1.48)		
Systemic corticosteroids	1.22 (1.17,1.28)		
Analgesics/antipyretics	1.21 (1.16,1.26)		
Antiarrhythmics	1.21 (1.12,1.30)		
		1.0 1.5	2.0


eFigure 2. Kaplan-Meier Plot for Risk of Any Syndromic Feature of PASC



eFigure 3. Kaplan-Meier Plot for Risk of Any Systemic Feature of PASC



eFigure 4. Kaplan-Meier Plot for Risk of Any Medication Feature of PASC



eFigure 5. Kaplan-Meier Plot for Risk of Any Syndromic, Systemic, or Medication Feature of PASC

